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Abstract: Leucine382 of cytochrome P450 1A2 (CYP1A2) plays an important role in binding and
O-dealkylation of phenacetin, with the L382V mutation increasing substrate oxidation (Huang and
Szklarz, 2010, Drug Metab. Dispos. 38:1039–1045). This was attributed to altered substrate binding
orientation, but no direct experimental evidence had been available. Therefore, in the current studies,
we employed nuclear magnetic resonance (NMR) longitudinal (T1 ) relaxation measurements to
investigate phenacetin binding orientations within the active site of CYP1A2 wild type (WT) and
mutants. Paramagnetic relaxation time (T1P ) for each proton of phenacetin was calculated from the
T1 value obtained from the enzymes in ferric and ferrous-CO state in the presence of phenacetin,
and used to model the orientation of phenacetin in the active site. All aromatic protons of phenacetin
were nearly equidistant from the heme iron (6.34–8.03 Å). In contrast, the distance between the proton
of the –OCH2 – group, which is abstracted during phenacetin oxidation, and the heme iron, was much
shorter in the L382V (5.93 Å) and L382V/N312L (5.96 Å) mutants compared to the N312L mutant
(7.84 Å) and the wild type enzyme (6.55 Å), consistent with modeling results. These studies provide
direct evidence for the molecular mechanism underlying increased oxidation of phenacetin upon the
L382V mutation.
Keywords: cytochromes P450; CYPs; P450 mutants; CYP1A2; T1 NMR; phenacetin oxidation

1. Introduction
Cytochromes P450 (P450s, CYPs) are heme-containing monoxygenase enzymes, which are
responsible for the oxidation of a large variety of drugs, carcinogens, and other xenobiotics in species
ranging from bacteria to humans. A P450 enzyme usually has the ability to metabolize a number of
different substrates, and different P450s often display overlapping substrate specificities and inhibitor
susceptibilities [1,2].
The CYP1A subfamily has two isoforms, 1A1 and 1A2, which display ~72% sequence identity
but exhibit different substrate specificities and inhibitor susceptibilities. CYP1A2 is one of the major
hepatic CYPs exclusively in human liver (~13–15%) and metabolizes about 15% of clinical drugs [3].
CYP1A2 was first characterized as phenacetin O-dealkylase [4], and phenacetin O-dealkylation has
been used as the most common marker reaction for CYP1A2 activity in the in vitro studies [5].
The crystal structure of CYP1A2 (Protein Data Bank ID: 2HI4) in complex with α-naphthoflavone
(ANF) has been solved by X-ray crystallography, with the structural refinement of 1.95 Å [6].
The compact active site is closed without apparent solvent or substrate access channels. The active site
cavity of CYP1A2 has a medium volume of 375 Å3 [6], which is larger than that of CYP2A6 (260 Å3 ) [7],
but much smaller than that of CYP3A4 and CYP2C8, with cavity volumes of 1385 Å3 and 1438 Å3 ,
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respectively [8,9]. The narrow substrate binding cavity of CYP1A2 is lined by residues on helices F and
I. The cavity of CYP1A2 is stabilized by strong hydrogen-bonding interactions between the side chain
of Thr223 on helix F and the side chain of Asp320 on helix I. Both Thr223 and Asp320 are involved in
an extensive network of hydrogen-bonded water molecules and side chains, including Tyr189, Val220,
Thr498, and Lys500 [6].
The crystal structure of CYP1A2 reveals that Leu382 is located near the heme iron, and thus
may play a role in determining substrate specificity. This is consistent with our previous findings
that the L382V mutation alters enzyme specificity with alkoxyresorufins and phenacetin [10–12].
Enzyme kinetics studies have shown that the L382V mutant and other multiple mutants containing the
L382V mutation displayed about 2-fold or 3-fold higher catalytic activities with phenacetin than the
wild type enzyme, while other single mutants, such as T124S, T223N, V227G, and N312L, showed much
lower activities [12]. In addition, molecular modeling studies have shown that the substitution of Leu
by a smaller Val allowed the substrate to move closer to the heme iron, thereby promoting hydrogen
abstraction and increasing P450 catalysis [12]. Although this explanation provided a plausible
mechanism for changes in the catalytic activities of the mutants, no direct experimental evidence
was available to support this hypothesis.
Therefore, in the current study, we used nuclear magnetic resonance (NMR) methods to further
investigate the above proposition. NMR longitudinal (T1 ) relaxation measurements provide an efficient
experimental method to elucidate the binding orientations of substrate within the active sites of
P450 [13,14]. In general, NMR-derived T1 relaxation time is shortened in a distance-dependent manner
when paramagnetic molecules, such as iron, are present [15,16]. Therefore, the distance of ligand
protons from the heme of P450 can be estimated by calculating the difference of T1 relaxation times
before and after P450 is bubbled with carbon monoxide and the T1 times of substrate protons closest to
the heme iron will show more significant decreases than T1 times of those farther away [15,16]. We had
previously reported the preferred binding orientations of phenacetin in CYP1A1 and 1A2 associated
with isoform-selective metabolism using this method [17]. The results have confirmed the importance
of residue 382 in CYP1A2-catalyzed oxidations and showed that a single residue substitution can
dramatically affect enzymatic activity.
In the present work, we compared the distances between the protons of phenacetin and heme-iron
in CYP1A2 wild type (WT) and the mutants to investigate the effects of single and multiple mutations
of CYP1A2 on phenacetin O-dealkylation. In addition, a molecular model was provided to illustrate
the different binding orientations of phenacetin in the active sites of CYP1A2 WT and the mutants
using the distance constraints derived from T1 NMR experiments.
2. Results
2.1. Purification of CYP1A2 Enzymes
The overall yields of purified enzymes were about 25–50%, similar to those reported
previously [10–12]. The purity of CYP1A2 enzymes was verified by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blots, which indicated that the proteins
were at least 95% pure. The ultraviolet/visible (UV/Vis) spectra of the purified enzymes were typical
of P450s purified mainly in the low spin form, while the spectra of the Fe2+ -CO complexes exhibited
the characteristic peak at 450 nm, indicative of little or no P420 formation. The holoenzyme content of
the enzymes was 40–60%, similarly as observed previously in our laboratory.
2.2. Interactions of Phenacetin with CYP1A2 Enzymes
The chemical structure along with the proton numbering scheme used for phenacetin is shown
in Figure 1. The P450 absorbance spectrum is sensitive to ligand binding and solution conditions,
and is composed of overlapping spectra of low spin (S = 1/2) and high spin (S = 5/2) states of the
heme [18]. The addition of different concentrations of phenacetin to purified CYP1A2 WT and mutants
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led to an increase of their Soret peak at 390 nm and a decrease of a band at 417 nm, as shown in
Figure 2A. Thus, for all enzymes, we observed a typical Type I spectrum, which indicates a change of
the spin state of the heme iron from low spin (S = 1/2) to high spin (S = 5/2) due to the binding of
the substrate to the protein in close proximity of heme [19]. The dependence of UV/Vis absorption
changes on the concentration of the substrate was used to calculate the spectral binding constants, Ks,
for the P450-phenacetin complexes at 27 ◦ C. Table 1 presents the Ks values for phenacetin binding
with CYP1A2 WT and the mutants. The Ks values for N312L, L382V, L382V/N312L mutants were
lower than that of the WT enzyme (Table 1, Figure 2B).

Figure 1. Structure of phenacetin with protons numbered as referenced in the text. Proton abstraction
occurs at the –OCH2 – group, which is the oxidation site.

Figure 2. Phenacetin binding determined for CYP1A2 wild type (WT) and the mutants by
ultraviolet/visible (UV/Vis) spectroscopy. (a) Spectral binding curves for phenacetin bound in CYP1A2
L382V. A type I spectrum is evident with a peak at ~390 nm and a trough at ~420 nm. CYP1A2 WT,
N312L and L382V/N312L have similar UV/Vis binding spectra (not shown); (b) Binding curves for
phenacetin in CYP1A2 WT and the L382V mutant and the KS values derived from fitting of the data to
Equation (1).
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Table 1. Spectral binding constants for phenacetin with purified CYP1A2 WT and the mutants at 27 ◦ C.
The two cuvettes contained 0.5 µM CYP1A2 WT or the mutant in 0.1 M phosphate buffer, pH 7.4,
with 20% glycerol. Difference spectra were obtained after the addition of increasing concentrations of
substrate to the sample cuvette.
Enzyme

Spectrum Type (λmax − λmin )

Ks

(nm)

(µM)

I (390–420)
I (390–420)
I (390–420)
I (390–420)

17.1 ± 0.6
10.2 ± 0.4
0.7 ± 0.1
3.5 ± 0.2

CYP1A2 WT
CYP1A2 N312L
CYP1A2 L382V
CYP1A2 L382V/N312L

2.3. Determination of Spin State in CYP1A2 Enzymes
The UV/Vis spectra (wavelength 320–500 nm) of CYP1A2 WT and the mutants can be
deconvoluted into a low-spin component (~416–420 nm), a high-spin component (~390–405 nm),
and δ bands (~360 nm). The concentrations of phenacetin used in the determination of spin state were
identical to those used in NMR T1 studies. The percentages of low and high spin calculated from the
Soret bands of CYP1A2 WT and the mutants in the absence and presence of substrate are shown in
Table 2. In the absence of substrate, CYP1A2 WT and the mutants, L312N, L382V, and L382V/N312L,
existed primarily in the low spin state (93–97% low spin). The addition of phenacetin increased
the percentage of high-spin enzyme approximately 2- to 3-fold. It is critical to know these relative
percentages for interpreting NMR data because the increasing percentage of high-spin state results in
paramagnetic broadening and shifting [20,21].
Table 2. Percentages of low spin and high spin in CYP1A2 WT and the mutants in the absence and the
presence of phenacetin at 27 ◦ C.
Enzyme (+Substrate)

Low Spin

High Spin
%

CYP1A2 WT (no substrate)
+Phenacetin
CYP1A2 N312L (no substrate)
+Phenacetin
CYP1A2 L382V (no substrate)
+Phenacetin
CYP1A2 L382V/N312L (no substrate)
+Phenacetin

90
73
94
86
95
79
94
83

10
27
6
14
5
21
6
17

To verify fast-exchange conditions, the temperature dependence of the T1 relaxation of the
substrate protons was used. The double reciprocal plots of T1p versus temperature for CYP1A2 WT,
L312N, L382V, and L382V/N312L mutants are shown in Figure 3. The positive slopes in the double
reciprocal plot of T1 p versus temperature indicate that the fast exchange condition is being met. Double
reciprocal plots of T1,Fe3+ or T1,Fe2+-CO versus temperature also have positive slopes (data not shown).
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Figure 3. Temperature dependence of T1P of phenacetin protons in the presence of CYP1A2 WT (a),
N312L (b), L382V (c), and L382V/N312L (d) mutants. Positive slopes indicate that the substrate bound
in the active site is in fast exchange with the surroundings. , phenacetin protons H2/6; #, H3/5;
N, CH2; 4, COCH3; , CH3.

2.4. Nuclear Magnetic Resonance (NMR) T1 Experiments
The 1 H NMR spectrum of phenacetin consists of five well-resolved signals (one NMR peak,
one triplet, one quadruplet, and two doublets) and some additional peaks reflecting contamination
(Figure 4). From the splitting and the relative area of the peaks, one doublet centered at 7.21 ppm
was assigned to the protons at positions 3 and 5 on the phenyl ring, while the other doublet with
the same peak area but centered at 6.90 ppm was assigned to the protons at positions 2 and 6 on the
phenyl ring. In contrast, –COCH3 , –CH3 and OCH2 – groups of phenacetin formed a singlet (centered at
2.04 ppm), a triplet (centered at 1.26 ppm), and a quadruplet (centered at 4.02 ppm) in the NMR spectrum,
respectively. The average distances between the substrate protons and the heme iron for phenacetin
with each of the enzymes, CYP1A2 WT, N312L, L382V, and L382V/N312L mutants, were obtained from
T1 relaxation experiments (Table 3). T1 relaxation times decreased for all protons of phenacetin in the
presence of enzymes compared to those measured in the presence of enzymes and carbon monoxide.
T1 relaxation times showed a substantial difference between the samples with and without carbon
monoxide. All the aromatic protons of phenacetin are nearly equidistant from the heme iron (6.34–8.03 Å).
However, the distance between the proton of the –OCH2 – group, which is abstracted during phenacetin
oxidation, and the heme iron is much shorter in the L382V mutant (5.93 Å) and L382V/N312L mutant
(5.96 Å) than that in WT (6.55 Å). In contrast, the distance between the proton of the –OCH2 – group and
the heme iron is longer in the N312L mutant (7.84 Å) than that in WT, consistent with previous molecular
modeling results. In addition, the distances obtained by averaging the 20 lowest energy conformations of
the phenacetin are also presented in Table 3. The distances between the protons of phenacetin and heme
iron obtained from molecular modeling were about 1 Å longer, but still correlate well with T1 data.
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Figure 4. Nuclear magnetic resonance (NMR) spectrum of the protons of phenacetin obtained under
conditions used for T1 measurements. The numbering scheme used is the same as shown in Figure 1.
Table 3. T1 relaxation rate-estimated distances of phenacetin protons from the heme iron of CYP1A2
WT and the mutants. Standard errors (SEs) for measurements are shown in parentheses. Errors in
the T1 values were those reported by the fitting routine. Errors in the reported distances (r) were
determined by propagation of error from the T1 calculation. Generally, the error is <10%.

2,6
3.5
–OCH2 –
–COCH3
–CH3

T1,Fe3+

T1,Fe2+-CO

rf

Rg

T1,Fe3+

T1,Fe2+-CO

rf

Rg

2.22 (0.11)
2.02 (0.04)
1.54 (0.15)
1.53 (0.07)
1.33 (0.07)

2.78 (0.05)
2.50 (0.01)
1.85 (0.18)
1.62 (0.06)
1.53 (0.06)

Å
6.76 (0.34)
6.72 (0.43)
6.55 (0.87)
7.85 (0.81)
6.69 (0.45)

8.25
8.32
8.01
9.44
8.64

2.28 (0.11)
2.39 (0.22)
2.43 (0.18)
1.64 (0.13)
2.03 (0.13)

3.06 (0.04)
3.21 (0.08)
4.10 (0.07)
1.87 (0.11)
2.82 (0.11)

Å
6.34 (0.31)
6.39 (0.28)
5.93 (0.31)
6.79 (0.71)
6.13 (0.89)

7.96
7.87
6.95
8.05
7.58

CYP1A2 L382V/N312Le

CYP1A2 N312L d

Proton a

2,6
3.5
–OCH2 –
–COCH3
–CH3

CYP1A2 L382V c

CYP1A2 WT b

Proton a

T1,Fe3+

T1,Fe2+-CO

R f (Å)

R g (Å)

T1,Fe3+

T1,Fe2+-CO

r f (Å)

R g (Å)

2.32 (0.10)
1.94 (0.09)
1.62 (0.04)
1.54 (0.12)
1.87 (0.12)

2.45 (0.10)
2.04 (0.10)
1.69 (0.04)
1.60 (0.11)
1.97 (0.07)

Å
8.03 (0.42)
7.94 (0.43)
7.84 (0.77)
8.19 (1.12)
7.83 (0.52)

9.11
9.38
8.67
9.34
8.94

2.43 (0.07)
2.95 (0.09)
1.98 (0.12)
2.12 (0.14)
2.23 (0.09)

3.00 (0.06)
3.70 (0.11)
2.90 (0.09)
2.59 (0.12)
2.61 (0.11)

Å
6.72 (0.31)
6.87 (0.47)
5.96 (0.35)
6.62 (0.15)
6.92 (0.34)

7.28
7.25
7.24
8.01
7.47

a

See Figure 1 for the numbering scheme of the protons for phenacetin; b [CYP1A2 WT] = 0.017 µM,
[phenacetin] = 171 µM, KS (CYP1A2 WT ) = 17.1 µM; c [CYP1A2 L382V] = 0.007 µM, [phenacetin] = 7 µM,
KS (CYP1A2 L382V) = 0.7 µM; d [CYP1A2 N312L] = 0.011 µM, [phenacetin] = 102 µM, KS (CYP1A2 N312L) = 10.2 µM;
e [CYP1A2 L382V/N312L] = 0.004 µM, [phenacetin] = 35 µM, K
f Values were
S (CYP1A2 L382V/N312L) = 3.5 µM;

1/6 g
16
calculated by r = 9.78 ∗ 10 T1P αm S(S + 1)τc
; Values were obtained by averaging the 20 lowest-energy
conformations selected by the docking program (See molecular dynamics (MD) Docking with Distance Restraints).

2.5. Position of Phenacetin Relative to Heme in CYP1A2 Wild Type (WT) and Mutants
3D models consisting of the substrate phenacetin and CYP1A2 WT and various mutants
that correspond to the NMR-derived proton-heme distances listed in Table 3 were constructed.
The enzyme-substrate interaction energies for various substrate conformations were never higher than
5 kcal/mol. Figure 5a displays the binding orientations of phenacetin within the active sites of CYP1A2
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WT and the L382V mutant. Additionally, in order to clearly identify each atom in phenacetin and the
distances between protons of phenacetin and heme iron, the cartoon diagram is presented as Figure 5b.
As shown in the figures, phenacetin displays similar binding orientations in both CYP1A2 WT and
L382V mutant. However, based on the final position after the restraint molecular dynamics (MD) run,
the protons of –OCH2 group of phenacetin, the site of metabolism, are closer to the heme-iron in the
L382V mutant (6.95 Å) than the WT (8.01 Å).

Figure 5. Binding of phenacetin in the active site of CYP1A2 WT and L382V. (a) A comparison of
phenacetin binding orientations in CYP1A2 WT (substrate shown in yellow), and in CYP1A2 L382V
(substrate shown in green). The enzymes were superimposed using the protein backbone as a basis;
for clarity, the mutant enzyme is not displayed; (b) Cartoon representation of (a) to clearly show the
distances of protons to heme iron. The heme is labeled and shown as a circle and a line, the distances
of protons of phenacetin to heme iron are listed and represented by dotted lines.

3. Discussion
The objective of the present study was to explore the structural basis for changes in CYP1A2
activity upon the substitution of residue Leu382 using phenacetin as a probe. Previous work has
demonstrated that all CYP1A2 mutants that contained the L382V substitution (L382V, L382V/T223N,
L382V/N312L, L382V/T223N/N312L, L382V/T124S/N312) displayed much higher phenacetin
oxidation activities than CYP1A2 WT, with Kcat values 3-fold higher, in contrast to other mutants
(T124S, T223N, V227G, and N312L), for which Kcat decreased [12]. Further stoichiometry studies
suggested that the CYP1A2 L382V mutants were more efficient in coupling NADPH to the product,
and displayed less uncoupling to water, leading to the increased overall coupling efficiency of the
enzyme [12]. Molecular modeling indicated that L382V substitution increased the volume of the active
site near the heme and allowed phenacetin to move closer to the heme, which promotes hydrogen
abstraction [12].
In order to provide direct evidence to support our previous findings, we investigated the
orientation of substrate phenacetin in the active site of CYP1A2 WT and its mutants using NMR
T1 relaxation measurements. This allowed us to calculate the distance between phenacetin protons and
heme iron in various CYP1A2 enzymes. Except for the –OCH2 – group, the substrate proton-heme iron
distances for CYP1A2 WT, L382V, N312L, and L382V/N312L were very similar, ranging from 6.1 to
8.2 Å. These values are similar to the distances between hydroxylation sites and the heme iron reported
for other P450 enzymes [15,17,22–26]. The distance between the protons of the –OCH2 – group and
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heme iron in CYP1A2 N312L was about 7.84 Å, which is much longer than that in CYP1A2 WT (6.55 Å).
In contrast, the distances in CYP1A2 L382V and L382V/N312L were 5.93 Å and 5.96 Å, respectively,
much closer to the heme iron than those of the WT enzyme (Table 3). Interestingly, the same distances
obtained from molecular modeling were 1–2 Å longer than those from the NMR data. The reason,
in part, might be because the distances calculated from MD are based on a very small subset of
orientations, while the distances calculated from the NMR T1 data represent a large number of possible
orientations. However, these values should be very similar if MD run time is sufficiently extended.
Previously, we had successfully used the T1 NMR methodology to estimate the distances between
the –OCH2 – protons of the ethoxy group (site of phenacetin O-deethylation) and the heme iron in both
CYP1A1 and CYP1A2 WTs [17]. The calculated distances were shorter in CYP1A2 WT than in CYP1A1
WT, indicating a more efficient metabolism of phenacetin by CYP1A2. Taken together, our findings
from the previous and current studies on CYP1A2 WT and the mutants provide a rationale for the
efficient phenacetin O-dealkylation by CYP1A2 WT and 1A2 mutants containing the substitution of
Leu-382 with a small Val. In contrast, CYP1A1 and CYP1A2 N312L metabolized phenacetin with
a very low efficiency, as shown in our previous studies [12].
The NMR T1 relaxation measurements were also used to examine the orientation of other
substrates within the active site of human CYP1A2. Regal and Nelson investigated the positioning of
caffeine in CYP1A2 and found that the averaged distance for the N3 group was shorter than those for
N1 and N7 groups [15], consistent with the known preference of the enzyme, which oxidizes caffeine
at the N3 position [27,28]. However, Regal and Nelson calculated the relevant distances using an
equation, r = C [ T1P αm f (τc )]1/6 , which did not take into account the fact that the spin state may change
upon substrate binding and, therefore, the value of C may be incorrect [29]. Thus, the authors had to
provide a range of distances, representing the change in the spin state of CYP1A2 ranging from 100%

1/6
low spin to 100% high spin. The modified equation, r = 9.78 × 1016 T1P αm S(S + 1)τc
, used in the
present work, shown as Equation (2), takes into the account the constant changes of spin state, and has
been widely used to calculate the distances in NMR T1 measurement in more recent studies [12,29,30].
A bias in the calculations leading to an overestimation of the distances can be introduced if
the exchange between the free and bound ligands is not fast enough to neglect the residence time
for the protons near the paramagnetic site [31]. To test the fast exchange condition, three different
temperatures: 283, 298, and 310 K were adapted to perform T1 relaxation measurements. The slopes
1/T1,Fe3+ , 1/T1,Fe2+-CO , and 1/T1p versus 1/temperature are all positive and show a good linear
relationship (R2 > 0.95) (Figure 3), which suggests that fast exchange exists.
NMR T1 relaxation measurements have been often used for investigating substrate orientation
in various P450s. However, it has not been applied as extensively as other spectroscopic
techniques due to the requirements for large amounts of highly purified enzymes and sufficiently
water-soluble substrates.
The interaction between phenacetin and CYP1A2 WT and the mutants resulted in a type I binding
spectrum (Figure 2a for CYP1A2 L382V, other data not shown), which indicates the interaction is
a competitive binding, in contrast to ligation of the inhibitor to the heme iron (type II binding) or
the formation of a metabolite inhibitory complex (MIC) by mechanism-based inhibitors (type III
binding) [32]. Although local single or multiple mutation of CYP1A2 did not change the interaction
type of substrate with enzyme, the binding capability altered significantly upon mutation. Ks values
indicate that phenacetin binds much tighter to CYP1A2 L382V and L382V/N312L than in the WT
and N312L (Table 1), as well as CYP1A1 [17]. This may indicate that phenacetin, and especially the
oxidation site, moves much closer to the heme iron in CYP1A2 L382V and L382V/N312L to form
a more stable complex.
Similar to previous findings with CYP1A1 WT and CYP1A2 WT [17], the ligand-free CYP1A2
WT and the mutants exhibited a high percentage of low spin state (90–95%), indicating that a water
molecule forms a sixth axial ligand of the Fe3+ in the substrate-free form. The percent of high spin P450
was substantially increased during co-incubation with the substrate phenacetin (Table 2) due to the
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displacement of the water ligand by the substrate. Although the percentages of high spin for CYP1A2
WT (17%), L382V (16%), and L382V/N312L (11%) were higher than for N312L (8%), the relationship
between binding affinity and the ability to increase the percentage of high spin state of the enzyme is
still unclear.
In summary, the substitution of Leu382 with a small Val in CYP1A2 led to the substrate phenacetin
moving closer to the heme, with the site of metabolism closer to the heme iron than in the WT enzyme.
Spectral binding studies revealed that the mutation of L382V significantly increased the affinity of the
mutants for phenacetin. These results demonstrate that both the distance between protons of phenacetin
and the heme iron, as well as the change in substrate binding affinity are likely responsible for altering
the catalytic efficiency of the enzyme, which is consistent with our previous findings regarding enzyme
kinetics and stoichiometry, as well as predictions from molecular modeling studies [12].
4. Materials and Methods
4.1. Materials
Phenacetin, dilauroyl-L-3-phosphatidyl choline (DLPC), sodium dithionite, polyvinyl pyrolidone
(PVP) and D2 O were purchased from Sigma-Aldrich (St. Louis, MO, USA). Potassium phosphate
and EDTA were purchased from Fisher Scientific (Pittsburgh, PA, USA). Emulgen® and Chaps® were
obtained from the Chemical Division of the KAO Corporation (Tokyo, Japan) and EMD Biosciences
(Lajolla, CA, USA), respectively. Deuterium oxide (D2 O, 99.9%) was obtained from Cambridge Isotope
Laboratory (Andover, MA, USA). Centricon 10 kDa MW cut-off filters were purchased from Millipore
Corporation (Billerica, MA, USA). Carbon monoxide was obtained from Mountain State AirGas
(Morgantown, WV, USA). All other chemicals were of analytical grade and were purchased from
standard commercial sources.
4.2. Protein Expression and Purification
CYP1A2 WT, two single mutants N312L and L382V, and a multiple mutant L382V/N312L,
were expressed and purified according to previously established methods [10–12]. Briefly,
the His-tag-containing CYP1A2 WT and mutants were expressed in Escherichia coli DH5α cells, and the
enzymes were purified by affinity chromatography with Ni-NTA agarose. During purification, 5 mM
caffeine was added to all the buffers to stabilize the enzyme. Subsequently, caffeine was removed
completely from the preparation at the ultrafiltration stage [12]. Rat P450 reductase was expressed
and purified as described earlier [10,33]. The purified enzyme fractions were aliquoted and stored at
−80 ◦ C for further use.
4.3. Binding Constant Determination
The interactions between the substrate phenacetin and purified CYP1A2 WT and mutants
were studied by difference visible spectroscopy [34] on a Beckman DU640 spectrophotometer
(Beckman Instruments Inc., Fullerton, CA, USA). Solutions (800 µL) contained 0.5 µM CYP1A2
enzymes in 100 mM phosphate buffer (20% glycerol and 0.1 mM EDTA, pH 7.4). The spectrophotometer
was set to record spectra from 350 to 500 nm. The temperature was held constant at 27 ◦ C.
Two microliters of different concentrations of solutions of phenacetin in methanol were added to
the sample cuvette, and the same volume of methanol was added to the reference, and UV/Vis spectra
were then recorded. The spectral binding constant (Ks) was derived from fitting of the data to Equation
(1) using GraphPad Prism 7 (GraphPad Software Inc., La Jolla, CA, USA):
∆A =

Bmax × [S]
Ks + [ S ]

(1)

where ∆A represents absorbance difference, Bmax is the maximum absorbance difference extrapolated
to infinite ligand concentration, and [S] is the substrate concentration.
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4.4. Spin State Determination
The percentages of high and low spin in CYP1A2 enzymes upon binding of phenacetin were
determined as previously described [32]. Spectral titrations with phenacetin in CYP1A2 enzymes
were performed by spectral scanning between 320 and 500 nm, with substrate concentrations
identical to those in NMR studies. By using multiple Gaussian curve fitting with the OriginPro
v8 package (OriginLab Corporation, Northampton, MA, USA), absorbance spectra were deconvoluted
into three components: a low-spin component, a high-spin component, and the broad δ-band.
The three components (δ-bands, low spin, and high spin) were used to fit data for phenacetin with
CYP1A2 enzymes and estimate percentages of low spin.
4.5. Enzyme Preparation for NMR
The procedure of sample preparation and incubation has been described in detail previously [17].
Briefly, 1% (w/v) PVP in 100 mM deuterated phosphate buffer was prepared and applied to the surface
of 10 kDa MW cutoff Centricon filter. The enzyme preparation was exchanged and concentrated
against 100 mM deuterated phosphate buffer over the Centricon filter by centrifugation (1000× g, 4 ◦ C)
for 3~4 times. The final enzyme preparation contained less than 1% glycerol and ~20 µM CYP1A2.
4.6. NMR Spectroscopy
NMR T1 relaxation studies were carried out on a Varian Inova NMR Spectrometer (Varian Inc,
Palo Alto, CA, USA) operating at 600 MHz, internally locked on the deuterium signal of the solvent,
deuterium oxide (D2 O), as described previously [17,29]. Signals were referenced internally to hydrogen
deuterium oxide (HDO) peak at 4.8 ppm. A standard inversion recovery sequence (d1 -180◦ -d2 -90◦ )
was utilized, along with presaturation of the residual HDO signal. The 90◦ pulse width was calibrated
on each sample. The preacquisition delay d1 was set to 10 × T1 (40 s) of the longest relaxation time.
The NMR spectra associated with at least 10 d2 values were needed. Line broadening and the Gaussian
fitting function were used for precise calculations of T1 values for the protons. The value of the
longitudinal relaxation time was obtained from the Varian software by using a nonlinear least-square
fitting of the peak height as a function of the delay d2 . T1 values were calculated from the substrate
solutions without the enzyme, and after the addition of the enzyme. The T1 (ferrous-CO) of the ligand
protons were measured after in situ conversion of the enzyme to its diamagnetic ferrous carbonyl
complex (Fe2+ -CO) by bubbling carbon monoxide for 15 min, followed by adding ~1 mg of sodium
dithionite. The sample was allowed to equilibrate for 30 min before T1 (ferrous-CO) measurement.
The final T1 (ferrous-CO) measurement of the ligands in presence of the Fe2+ -CO complex and the T1 of
the enzyme-free ligand were nearly identical, which indicates very little paramagnetic contribution
due to impurities. The integrity of the enzyme was assayed by measuring the UV/Vis spectra of
samples maintained under similar conditions. No significant P420 formation was observed throughout
the experiment.
To validate the fast-exchange conditions, the temperature dependence of T1P was studied at
three different temperatures (283, 298, and 310 K). Experiments involving enzyme titration studies
with CYP1A2 WT and the mutants were performed with phenacetin as a substrate. Concentrated
enzyme was added to the substrate in small increments, and the T1 measurements were performed
after each addition.
4.7. Proton-Heme Iron Distance Calculations
A more precise method for the distance (r) calculation using spin-state data was adopted,
described in details earlier [17,29]. Briefly, the calculation for distance can be written as Equation (2):
i1/6
h
r = 9.78 × 1016 T1P αm S(S + 1)τc

(2)
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The distance is given by r. The tumbling coefficient τ c, calculated by measuring T1P at several
magnetic field strengths, represents the correlation time of the dipolar interactions of the protein in
solution [16]. An estimate for τ c of CYP1A2 is 3.38 × 10−10 s−1 , as reported previously [15]. T1P is the
portion of T1 due to paramagnetic affects alone and is given by Equation (3):
1
1
1
=
−
T1P
T1,Fe3+
T1,Fe2+ −CO

(3)

assuming that all of the diamagnetic contribution is represented by 1/T1,Fe2+-CO [15]. This assumption
appears to be generally valid when used in many similar studies [25,35]. The parameter αm ,
[P450]
the fractional binding coefficient, is obtained by the equation αm = K +[S] under conditions of
S
fast exchange when only one substrate is present [15]. Ks values determined from visible spectroscopy
were utilized for the distance calculations rather than KD determined by NMR for phenacetin because of
the equal or slight difference between Ks and KD based on Michaelis–Menten kinetics [15]. The S(S + 1)
term was simplified by Equation (4) [29].
S(S + 1) = 8.75 f HS + 0.75 f LS

(4)

where fHS and fLS refer to the fractions of the high spin and low spin iron, respectively [29].
4.8. Molecular Modeling: General
All molecular modeling was conducted by Insight II software (Accelrys, San Diego, CA, USA)
on a Silicon Graphics Octane workstation. Phenacetin was constructed and minimized using the
Insight II/Builder module. Energy minimization and MD simulations were performed by the Insight
II/Discover module with the consistent valence force field (CVFF). The parameters for heme containing
Fe3+ had been described earlier [17,36,37].
4.9. Substrate Docking with Distance Restraints
Phenacetin as substrate was initially placed into the active sites of both CYP1A2 WT and the mutants
manually to avoid steric overlaps. Automated docking of ligands was then conducted by the Insight
II/Affinity module using default parameters, as previously described [10,12,17,38], except that the ferric
form of the heme was used. After 20 positions (or poses) were obtained, the most energetically favorable
complex was chosen and subjected to MD simulations and minimization with NMR-based distance
restraints imposed. The protein backbone was tethered to its initial coordinates by a harmonic restraint
force to avoid possible protein deformation resulting from restraint forces. Substrate protons were
guided to NMR-derived distances from the heme iron by applying gradually strengthening harmonic
restraint (k = 2 − 32 kcal·mol−1 · A−1 ) throughout 5 ps of MD. The non-bond cutoff parameter was
15 Å, and a screened Coulomb potential with a distance-dependent dielectric was used to simulate an
aqueous solvent environment. After MD simulations, the final frame of the trajectory was minimized to
convergence while the distance restraints were maintained during the minimization.
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